Exagen Diagnostics Names Dr. Thomas Williams Chief Science Officer and Vice President, Research and Development
Posted on: Monday, 6 March 2006, 09:01 CST
ALBUQUERQUE, N.M., March 6 /PRNewswire/ -- Exagen Diagnostics, Inc., which develops and commercializes genomic marker-based in vitro diagnostic (IVD) kits for prognosis and prediction of treatment response, today announced that Dr. Thomas Williams has been named chief science officer and vice president, research and development. Williams will spearhead the company's scientific strategy, including genomic marker validation, product development functions and collaborative relationships with key customers.
"Exagen has benefited from Tom's expertise since the company's inception," said Exagen CEO James McClintic. "His extensive record of accomplishment in clinical molecular diagnostics, molecular genetics research and clinical research makes him the ideal person to direct our scientific efforts as we bring our products to market."
Prior to joining Exagen as a full-time employee, Williams served as the company's special advisor for molecular pathology. Additionally, he was vice chairman, department of pathology, at the University of New Mexico (UNM) School of Medicine and director of the Genetics and Cytometry Division at TriCore Reference Laboratories, a regional medical laboratory affiliated with UNM Health Sciences Center and Presbyterian Healthcare Services. Williams will continue with UNM as part-time professor of pathology.
About Exagen Diagnostics, Inc.
An emerging leader in the development of prognostic and predictive in vitro diagnostic (IVD) kits, Exagen is uniquely able to discover, validate and productize small sets of genomic markers for use in oncology, infectious disease and other indications. The company's first tests predict the risk of breast cancer recurrence, so that women with a low or elevated risk of recurrence can be identified with high accuracy. Exagen plans to submit its tests to the Food and Drug Administration for clearance later this year, and will be the first to market a set of genomic markers for breast cancer prognosis using a fluorescent in situ hybridization (FISH) test. For more information, visit http://www.exagen.com/.
Exagen Diagnostics, Inc.
CONTACT: Ellen Mather, Director, Public Relations, Exagen Diagnostics,Inc., +1-505-828-9093, emather@exagen.com
Web site: http://www.exagen.com/
Source: PRNewswire
Related Articles
- Exagen Diagnostics(TM), Inc. Announces an Oral Presentation of a Clinical Study on Genomic Biomarkers for Breast Cancer at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
- Exagen Diagnostics, Inc.(TM) Adds Marketing Director
- Exagen Diagnostics, Inc.(TM) Leads Next Phase of Genomics Revolution
- Exagen Diagnostics Adds Marketing Director
- Exagen Diagnostics Creates an Executive Committee and Adds Corporate Controller
- Exagen Diagnostics Names Luc Van Hove Vice President, Quality, Regulatory, Medical Affairs and Chief Medical Officer
- Exagen Diagnostics Names Thomas O'Connor Vice President, Sales
- Exagen Diagnostics Names Robert Mignatti President and Chief Operating Officer
- Exagen Diagnostics Names James McClintic CEO
 |
 |
User Comments (0)
RSS Feeds